Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Cost of Revenue (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Cost of Revenue for 5 consecutive years, with $826000.0 as the latest value for Q1 2018.

  • On a quarterly basis, Cost of Revenue rose 46.19% to $826000.0 in Q1 2018 year-over-year; TTM through Mar 2018 was $6.3 million, a 134.65% increase, with the full-year FY2017 number at $6.0 million, up 108.36% from a year prior.
  • Cost of Revenue was $826000.0 for Q1 2018 at Theravance Biopharma, down from $3.1 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $3.2 million in Q4 2014 to a low of $188000.0 in Q1 2014.
  • A 5-year average of $1.1 million and a median of $638000.0 in 2016 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: crashed 64.19% in 2016, then surged 196.69% in 2017.
  • Theravance Biopharma's Cost of Revenue stood at $3.2 million in 2014, then dropped by 0.68% to $3.2 million in 2015, then plummeted by 64.19% to $1.1 million in 2016, then surged by 171.9% to $3.1 million in 2017, then crashed by 73.49% to $826000.0 in 2018.
  • Per Business Quant, the three most recent readings for TBPH's Cost of Revenue are $826000.0 (Q1 2018), $3.1 million (Q4 2017), and $985000.0 (Q3 2017).